VX A601
Alternative Names: VX-A601Latest Information Update: 21 Nov 2023
At a glance
- Originator VERAXA Biotech
- Developer Merck AG; VERAXA Biotech
- Class Antineoplastics; Monoclonal antibodies
- Mechanism of Action Immunomodulators
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Research Cancer
Most Recent Events
- 29 Sep 2023 Early research in Cancer in Germany (Parenteral) (Veraxa Biotech pipeline, September 2023)